Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Division of Microbiology, Calgary Laboratory Services, Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada. johann.pitout@cls.ab.ca
The medical community relies on clinical expertise and published guidelines to assist physicians with choices in empirical therapy for system-based infectious syndromes, such as community-acquired pneumonia and urinary-tract infections (UTIs). From the late 1990s, multidrug-resistant Enterobacteriaceae (mostly Escherichia coli) that produce extended-spectrum beta lactamases (ESBLs), such as the CTX-M enzymes, have emerged within the community setting as an important cause of UTIs. Recent reports have also described ESBL-producing E coli as a cause of bloodstream infections associated with these community-onset UTIs. The carbapenems are widely regarded as the drugs of choice for the treatment of severe infections caused by ESBL-producing Enterobacteriaceae, although comparative clinical trials are scarce. Thus, more rapid diagnostic testing of ESBL-producing bacteria and the possible modification of guidelines for community-onset bacteraemia associated with UTIs are required.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on